|
|
|
AP Liao, et al. / public library of science
|
The paper:
M.J. Evans, et al., "Claudin1 is a hepatitis C virus co-receptor required for
a late step in entry," Nature, 446:801-5, 2007. (Cited in 81 papers)
The finding:
In attempts to find out why hepatitis C virus (HCV) would not infect any cell
type except liver, Matthew Evans at The Rockefeller University and colleagues
expressed liver proteins in kidney cells and screened for HCV infection. The
researchers found claudin-1, a tight junction protein which binds epithelial cells
together at their sides, allowed the virus to infect a non-liver cell.
The impact:
Current antiviral drugs that target some aspect of viral replication are
usually not effective for very long; "viruses realize ways to sneak around" and
resist the drug, says Evans. Blocking an entry protein, like claudin-1, on the host
would strengthen any combination therapy for hepatitis C, a leading cause of liver
failure.
The big picture:
The finding adds to a growing body of literature that implicates tight
junction proteins in viral entry, says Alan Yu, a nephrologist at the University of
Southern California Keck School of Medicine. The viruses essentially are a ligand
for relaxing cellular tight junctions-a finding that could be useful in drug
delivery technology, says Yu.
| The numbers: |
|
claudin-1 inserted: Kidney cell infection increased 300 fold |
|
claudin-1 silenced: Liver cell infection inhibited 50 fold |